Beam Therapeutics Inc.

NasdaqGS:BEAM Voorraadrapport

Marktkapitalisatie: US$2.4b

Beam Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Beam Therapeutics is John Evans, benoemd in Apr2017, heeft een ambtstermijn van 7.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.28M, bestaande uit 10.9% salaris en 89.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.1% van de aandelen van het bedrijf, ter waarde $ 26.60M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.2 jaar en 4.5 jaar.

Belangrijke informatie

John Evans

Algemeen directeur

US$6.3m

Totale compensatie

Percentage CEO-salaris10.9%
Dienstverband CEO7.6yrs
Eigendom CEO1.1%
Management gemiddelde ambtstermijn5.2yrs
Gemiddelde ambtstermijn bestuur4.5yrs

Recente managementupdates

Recent updates

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 07

Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Oct 28
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy

Sep 29

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Sep 04
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Jul 12
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Beam Therapeutics: Slow Developmental Progress, But Promising Potential

Jul 01

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

May 13
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects

Apr 24

Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Apr 07
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Feb 29
Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now

Feb 08

This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

Nov 01
This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Jul 23
We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Apr 08
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Beam Therapeutics: Now Is Not The Right Time To Own

Sep 15

Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M

Aug 09

Beam drops 19% as FDA issues clinical hold on blood cancer candidate

Aug 01

Revisiting Beam Therapeutics Among Collaborative Catalysts

Jul 10

Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

May 10
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

Beam Therapeutics Worth Watching Because Of Pfizer Interest?

Apr 21

Beam Therapeutics: Getting More And More Interesting

Apr 10

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 03
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy

Jan 19

Beam Therapeutics: An Early Company In A Promising Field

Dec 27

Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity

Dec 20

Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio

Oct 01

Analyse CEO-vergoeding

Hoe is John Evans's beloning veranderd ten opzichte van Beam Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$144m

Jun 30 2024n/an/a

-US$143m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$6mUS$685k

-US$133m

Sep 30 2023n/an/a

-US$314m

Jun 30 2023n/an/a

-US$327m

Mar 31 2023n/an/a

-US$316m

Dec 31 2022US$9mUS$650k

-US$289m

Sep 30 2022n/an/a

-US$315m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$238m

Dec 31 2021US$14mUS$590k

-US$371m

Sep 30 2021n/an/a

-US$401m

Jun 30 2021n/an/a

-US$408m

Mar 31 2021n/an/a

-US$366m

Dec 31 2020US$907kUS$529k

-US$196m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$119m

Mar 31 2020n/an/a

-US$106m

Dec 31 2019US$2mUS$473k

-US$91m

Sep 30 2019n/an/a

-US$86m

Jun 30 2019n/an/a

-US$134m

Mar 31 2019n/an/a

-US$124m

Dec 31 2018US$4mUS$441k

-US$117m

Compensatie versus markt: De totale vergoeding ($USD 6.28M ) John } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.59M ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

John Evans (46 yo)

7.6yrs

Tenure

US$6,280,099

Compensatie

Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2020. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
John Evans
CEO & Director7.6yrsUS$6.28m1.1%
$ 26.6m
Giuseppe Ciaramella
President4.8yrsUS$2.79m0.057%
$ 1.4m
Christine Bellon
Senior VP5.6yrsUS$2.28m0.054%
$ 1.3m
Amy Simon
Chief Medical Officer3.7yrsUS$2.55m0.0017%
$ 41.5k
Feng Zhang
Co-Founderno datageen gegevensgeen gegevens
David Liu
Co-Founderno datageen gegevensgeen gegevens
J. Joung
Co-Founderno datageen gegevensgeen gegevens
Bethany Cavanagh
Senior VP of Finance & Treasurerno datageen gegevens0.0082%
$ 199.0k
Manmohan Singh
Chief Technology Officerno datageen gegevensgeen gegevens
Gopi Shanker
Chief Scientific Officer1.7yrsgeen gegevensgeen gegevens
Susan O'Connor
Chief Human Resources Officer7.3yrsgeen gegevensgeen gegevens
Brian Riley
Chief Manufacturing Officerno datageen gegevensgeen gegevens

5.2yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BEAM is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.2 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
John Evans
CEO & Directorno dataUS$6.28m1.1%
$ 26.6m
John M. Maraganore
Independent Director3yrsUS$435.22k0%
$ 0
Mark Fishman
Independent Lead Director6.5yrsUS$465.22k0.021%
$ 516.2k
Graham Cooper
Independent Director5.1yrsUS$450.22k0%
$ 0
Kathleen Walsh
Independent Director3.8yrsUS$447.72k0%
$ 0
Christi Shaw
Independent Directorless than a yearUS$772.68kgeen gegevens
Carole Ho
Independent Director6yrsUS$442.72k0%
$ 0

4.5yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BEAM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).